keyword
MENU ▼
Read by QxMD icon Read
search

Elderly, chemotherapy, lung cancer

keyword
https://www.readbyqxmd.com/read/29326090/the-addition-of-chemotherapy-to-radiation-therapy-improves-survival-in-elderly-patients-with-stage-iii-non-small-cell-lung-cancer
#1
Eric D Miller, James L Fisher, Karl E Haglund, John C Grecula, Meng Xu-Welliver, Erin M Bertino, Kai He, Peter G Shields, David P Carbone, Terence M Williams, Gregory A Otterson, Jose G Bazan
INTRODUCTION: Elderly patients represent the majority of lung cancer diagnoses but are poorly represented in clinical trials. We evaluated the overall survival (OS) of elderly patients with stage III non-small cell lung cancer (NSCLC) treated with definitive radiation compared to those treated with definitive chemoradiation. METHODS: We conducted a comparative effectiveness study of radiation therapy vs. chemoradiation in elderly (≥70 years old) patients with stage III NSCLC not treated surgically diagnosed from 2003-2014 using the National Cancer Database...
December 18, 2017: Journal of Thoracic Oncology
https://www.readbyqxmd.com/read/29316288/carboplatin-plus-pemetrexed-for-the-elderly-incurable-chemo-naive-nonsquamous-non-small-cell-lung-cancer-meta-analysis
#2
Masaru Ito, Nobuyuki Horita, Akimichi Nagashima, Takeshi Kaneko
AIM: In some developed countries, a proportion of nonsquamous non-small cell lung cancer (NSq NSCLC) patients are aged over 70 years when they are diagnosed. However, evidence of lung cancer chemotherapy usually comes from randomized controlled trials that only recruit younger patients with good performance status. In daily practice, less-toxic carboplatin + pemetrexed regimen is often used for elderly patients, although this regimen is not sufficiently supported by rigid evidence for elderly cases...
January 8, 2018: Asia-Pacific Journal of Clinical Oncology
https://www.readbyqxmd.com/read/29290260/high-expression-of-topoisomerase-ii-predicts-favorable-clinical-outcomes-in-patients-with-relapsed-small-cell-lung-cancers-receiving-amrubicin
#3
Yosuke Miura, Kyoichi Kaira, Reiko Sakurai, Noriaki Sunaga, Ryusei Saito, Takeshi Hisada, Masanobu Yamada
OBJECTIVES: Amrubicin monotherapy is a treatment option for patients with relapsed small cell lung cancers (SCLCs). Topoisomerase-II (Topo-II) - a target of amrubicin - has been reported as a predictive or prognostic marker for chemosensitivity or outcomes in patients with various malignancies. Here, we investigated the prognostic role of Topo-II expression in patients with relapsed SCLCs who underwent amrubicin monotherapy. MATERIALS AND METHODS: Eighty-three patients with relapsed SCLCs who received amrubicin monotherapy between 2004 and 2015, after progression beyond first-line chemotherapy, were enrolled in the study...
January 2018: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29276417/bevacizumab-in-the-treatment-of-nsclc-patient-selection-and-perspectives
#4
REVIEW
Alessia E Russo, Domenico Priolo, Giovanna Antonelli, Massimo Libra, James A McCubrey, Francesco Ferraù
Non-small-cell lung cancer (NSCLC) represents about 85% of all lung cancers, and more than half of NSCLCs are diagnosed at an advanced stage. Chemotherapy has reached a plateau in the overall survival curve of about 10 months. Therefore, in last decade novel targeted approaches have been developed to extend survival of these patients, including antiangiogenic treatment. Vascular endothelial growth factor (VEGF) signaling pathway plays a dominant role in stimulating angiogenesis, which is the main process promoting tumor growth and metastasis...
2017: Lung Cancer: Targets and Therapy
https://www.readbyqxmd.com/read/29212082/risk-factors-for-chemotherapy-related-toxicity-and-adverse-events-in-elderly-thai-cancer-patients-a-prospective-study
#5
Ekkamol Phaibulvatanapong, Varalak Srinonprasert, Suthinee Ithimakin
OBJECTIVES: To assess factors predisposing to severe chemotherapy-related toxicity and adverse events (AEs) and dose modification in aging cancer patients. METHODS: Cancer patients aged ≥70 years scheduled to receive the first cycle of a new chemotherapy regimen were enrolled. On the day of starting chemotherapy, demographic data, performance status (PS), and geriatric parameters were recorded. AEs and chemotherapy modification were recorded. Quality of life (QOL) was assessed at baseline and 3 months after starting chemotherapy or at the end of chemotherapy...
December 7, 2017: Oncology
https://www.readbyqxmd.com/read/29208355/usage-of-prophylactic-cranial-irradiation-in-elderly-patients-with-small-cell-lung-cancer
#6
Ronald A M Damhuis, Suresh Senan, Jose S Belderbos
BACKGROUND: Prophylactic cranial irradiation (PCI) reduces the risk of overt brain metastases in patients with small-cell lung cancer (SCLC) and is currently recommended in guidelines for both limited and extensive disease. Given the concerns about the greater frequency of neurologic side effects in elderly patients, we studied the association among age, PCI usage, and survival for SCLC patients in the Netherlands. PATIENTS AND METHODS: Data from the Netherlands Cancer Registry for patients diagnosed with SCLC from 2009 to 2013 were queried...
November 21, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29191594/a-phase-ii-trial-of-carboplatin-plus-s-1-for-elderly-patients-with-advanced-non-small-cell-lung-cancer-with-wild-type-epidermal-growth-factor-receptor-the-okayama-lung-cancer-study-group-trial-1202
#7
Shoichi Kuyama, Nobuaki Ochi, Akihiro Bessho, Katsuyuki Hotta, Genyo Ikeda, Daizo Kishino, Toshio Kubo, Daijiro Harada, Nobukazu Fujimoto, Masamoto Nakanishi, Takahiro Umeno, Toshiaki Okada, Kenichi Chikamori, Tomoko Yamagishi, Kadoaki Ohashi, Eiki Ichihara, Nagio Takigawa, Mitsune Tanimoto, Katsuyuki Kiura
INTRODUCTION: S-1 is an oral fluoropyrimidine-based combination of tegafur, gimeracil, and oteracil potassium. Although the combination of S-1 with carboplatin is a first-line chemotherapy regimen for advanced non-small cell lung cancer (NSCLC), the efficacy and safety of the regimen in the elderly remain unknown. METHODS: The patient inclusion criteria were previously untreated advanced NSCLC, wild-type epidermal growth factor receptor, aged 70 years or more, and a performance status (PS) of 0-2...
October 2017: Lung Cancer: Journal of the International Association for the Study of Lung Cancer
https://www.readbyqxmd.com/read/29183294/serum-albumin-level-as-a-potential-marker-for-deciding-chemotherapy-or-best-supportive-care-in-elderly-advanced-non-small-cell-lung-cancer-patients-with-poor-performance-status
#8
Satoshi Ikeda, Hiroshige Yoshioka, Satoshi Ikeo, Mitsunori Morita, Naoyuki Sone, Takashi Niwa, Akihiro Nishiyama, Toshihide Yokoyama, Akimasa Sekine, Takashi Ogura, Tadashi Ishida
BACKGROUND: There have been few data on the chemotherapy in elderly advanced non-small cell lung cancer (NSCLC) patients with poor performance status (PS), and usefulness of chemotherapy for such patients remains unclear. The objective of this study was to identify factors that predicted the survival benefit of chemotherapy. METHODS: All consecutive elderly patients (≥75 years) with advanced NSCLC, Eastern Cooperative Oncology Group PS ≥2, EGFR mutation wild type/unknown, and newly diagnosed from January 2009 to December 2012 at a tertiary hospital were retrospectively reviewed...
November 28, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29183277/unfavorable-impact-of-cancer-cachexia-on-activity-of-daily-living-and-need-for-inpatient-care-in-elderly-patients-with-advanced-non-small-cell-lung-cancer-in-japan-a-prospective-longitudinal-observational-study
#9
Tateaki Naito, Taro Okayama, Takashi Aoyama, Takuya Ohashi, Yoshiyuki Masuda, Madoka Kimura, Hitomi Shiozaki, Haruyasu Murakami, Hirotsugu Kenmotsu, Tetsuhiko Taira, Akira Ono, Kazushige Wakuda, Hisao Imai, Takuya Oyakawa, Takeshi Ishii, Shota Omori, Kazuhisa Nakashima, Masahiro Endo, Katsuhiro Omae, Keita Mori, Nobuyuki Yamamoto, Akira Tanuma, Toshiaki Takahashi
BACKGROUND: Cancer cachexia in elderly patients may substantially impact physical function and medical dependency. The aim of this study was to estimate the impact of cachexia on activity of daily living (ADL), length of hospital stay, and inpatient medical costs among elderly patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy. METHODS: Thirty patients aged ≥70 years with advanced NSCLC (stage III-IV) scheduled to receive first-line chemotherapy were prospectively enrolled between January 2013 and November 2014...
November 28, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29175386/impact-of-clinicopathologic-features-on-the-efficacy-of-pd-1-pd-l1-inhibitors-in-patients-with-previously-treated-non-small-cell-lung-cancer
#10
Tao Jiang, Hongcheng Liu, Meng Qiao, Xuefei Li, Chao Zhao, Chunxia Su, Shengxiang Ren, Caicun Zhou
BACKGROUND: The current study aimed to comprehensively investigate the impact of various clinicopathologic features on the efficacy of programmed cell death-1 (PD-1) and ligand (PD-L1) inhibitors in patients with previously treated non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Randomized controlled trials that compared PD-1/PD-L1-inhibitor monotherapy with chemotherapy or placebo in patients with previously treated NSCLC were included. RESULTS: Five trials were included (n = 3025)...
November 9, 2017: Clinical Lung Cancer
https://www.readbyqxmd.com/read/29156802/efficacy-and-safety-of-first-line-pemetrexed-plus-carboplatin-followed-by-single-agent-pemetrexed-maintenance-in-elderly-chinese-patients-with-non-squamous-non-small-cell-lung-cancer
#11
Xinmin Zhao, Hui Yu, Jing Zhao, Xianghua Wu, Si Sun, Zhiguo Luo, Huijie Wang, Jie Qiao, Jianhua Chang, Jialei Wang
Chemotherapy with pemetrexed plus carboplatin followed by pemetrexed maintenance therapy is a first-line regimen for patients with advanced non-squamous non-small-cell lung cancer. This phase II clinical study investigated the efficacy and safety of this regimen in older patients (aged ≥65 years) with advanced non-squamous non-small-cell lung cancer. All patients received 4 courses of induction therapy with pemetrexed (500 mg/m(2)) combined with carboplatin once every 3 weeks. If patients had stable disease or achieved a complete or partial tumor response after 4 courses of pemetrexed + carboplatin therapy, maintenance treatment with pemetrexed monotherapy was administered until either disease progression or intolerable toxicity occurred...
October 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/29123416/frequency-and-clinical-relevance-of-egfr-mutations-and-eml4-alk-translocations-in-octogenarians-with-non-small-cell-lung-cancer
#12
Amanda Tufman, Kathrin Kahnert, Thomas Duell, Diego Kauffmann-Guerrero, Katrin Milger, Christian Schneider, Julia Stump, Zulfiya Syunyaeva, Rudolf Maria Huber, Simone Reu
Background: Tyrosine kinase inhibitors (TKIs) have improved response rates in some patients with non-small cell lung cancer (NSCLC), and testing for EGFR mutation and ALK translocation is recommended for all patients with advanced lung adenocarcinoma. The frequency of driver mutations in elderly and very elderly patients has not been described. Patients and methods: We reviewed EGFR and ALK in patients over the age of 70 years diagnosed and treated at our center in 2015 (subgroups: 70-74, 75-79 and >80 years)...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28940851/multidisciplinary-decision-making-regarding-chemotherapy-for-lung-cancer-patients-an-age-based-comparison
#13
K J G Schulkes, M E Hamaker, J-W J Lammers, M T M van Rens, M Geerts, L J R van Elden
Optimising decision-making in elderly patients is becoming increasingly urgent. We analysed treatment decisions and course of therapy for patients with lung cancer in different age categories: <65, 65-75, and 75 years and older. About 349 patients with lung cancer (median age 67.8 years), discussed at the multidisciplinary team meeting in the Diakonessenhuis Utrecht, the Netherlands, were reviewed. Multidisciplinary decision-making and subsequent clinical course were extracted from medical files. We found that 39% of eligible patients older than 75 years of age started treatment with chemotherapy compared to 80% of the younger patients (<65 and 65-75)...
September 21, 2017: European Journal of Cancer Care
https://www.readbyqxmd.com/read/28841858/skeletal-muscle-depletion-during-chemotherapy-has-a-large-impact-on-physical-function-in-elderly-japanese-patients-with-advanced-non-small-cell-lung-cancer
#14
Tateaki Naito, Taro Okayama, Takashi Aoyama, Takuya Ohashi, Yoshiyuki Masuda, Madoka Kimura, Hitomi Shiozaki, Haruyasu Murakami, Hirotsugu Kenmotsu, Tetsuhiko Taira, Akira Ono, Kazushige Wakuda, Hisao Imai, Takuya Oyakawa, Takeshi Ishii, Shota Omori, Kazuhisa Nakashima, Masahiro Endo, Katsuhiro Omae, Keita Mori, Nobuyuki Yamamoto, Akira Tanuma, Toshiaki Takahashi
BACKGROUND: Elderly patient with advanced cancer is one of the most vulnerable populations. Skeletal muscle depletion during chemotherapy may have substantial impact on their physical function. However, there is little information about a direct relationship between quantity of muscle and physical function. We sought to explore the quantitative association between skeletal muscle depletion, and muscle strength and walking capacity in elderly patients with advanced non-small cell lung cancer (NSCLC)...
August 25, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28829693/effect-of-palliative-care-on-aggressiveness-of-end-of-life-care-among-patients-with-advanced-cancer
#15
Daniel P Triplett, Wendi G LeBrett, Alex K Bryant, Andrew R Bruggeman, Rayna K Matsuno, Lindsay Hwang, Isabel J Boero, Eric J Roeland, Heidi N Yeung, James D Murphy
PURPOSE: Palliative care's role in oncology has expanded, but its effect on aggressiveness of care at the end of life has not been characterized at the population level. METHODS: This matched retrospective cohort study examined the effect of an encounter with palliative care on health-care use at the end of life among 6,580 Medicare beneficiaries with advanced prostate, breast, lung, or colorectal cancer. We compared health-care use before and after palliative care consultation to a matched nonpalliative care cohort...
September 2017: Journal of Oncology Practice
https://www.readbyqxmd.com/read/28790841/relationship-between-ugt1a1-6-28-gene-polymorphisms-and-the-efficacy-and-toxicity-of-irinotecan-based-chemotherapy
#16
Yu Bai, Hai-Wei Wu, Xu Ma, Ying Liu, Yan-Hua Zhang
PURPOSE: A retrospective study was performed to analyze the relationship between uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) *6/*28 gene polymorphisms and adverse reactions associated with irinotecan (CPT-11)-based chemotherapy. The correlation between UGT1A1 polymorphisms and the clinical efficacy of CPT-11 was also analyzed, along with the influence of age and tumor type. PATIENTS AND METHODS: Patients administered a CPT-11-based regimen in the Beijing Cancer Hospital from April 2015 to September 2016 were included in our study (n=81)...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28771961/phase-i-study-of-pemetrexed-and-concurrent-radiotherapy-for-previously-untreated-elderly-patients-with-locally-advanced-non-squamous-non-small-cell-lung-cancer
#17
Shinnosuke Takemoto, Yoichi Nakamura, Minoru Fukuda, Hiroaki Senju, Hiroshi Gyotoku, Hirokazu Taniguchi, Midori Shimada, Takaya Ikeda, Hiroyuki Yamaguchi, Katsumi Nakatomi, Nobuyuki Hayashi, Hiroshi Soda, Hiroshi Mukae
BACKGROUND: Chemoradiotherapy is the standard treatment for locally advanced non-small cell lung cancer (NSCLC); however, it is disputed whether this treatment is suitable for patients aged ≥75. This study was conducted to determine the maximum tolerated dose (MTD) of pemetrexed for use in concurrent radiotherapy for elderly patients with locally advanced non-squamous NSCLC. METHODS: The eligibility criteria were as follows: aged ≥75 with inoperable stage IIIA or IIIB non-squamous NSCLC, no history of chemotherapy or radiotherapy, a performance status of 0 or 1, and adequate organ function...
November 2017: Thoracic Cancer
https://www.readbyqxmd.com/read/28763691/treatment-of-elderly-patients-or-patients-who-are-performance-status-2-ps2-with-advanced-non-small-cell-lung-cancer-without-epidermal-growth-factor-receptor-egfr-mutations-and-anaplastic-lymphoma-kinase-alk-translocations-still-a-daily-challenge
#18
REVIEW
Chunxia Su, Fei Zhou, Jiqiao Shen, Jing Zhao, Mary O'Brien
Cytotoxic chemotherapy remains the core treatment strategy for patients with advanced non-small cell lung cancer (NSCLC) with tumours that do not have actionable molecular alterations, such as epidermal growth factor receptor (EGFR)-sensitising mutations, anaplastic lymphoma kinase (ALK) translocations or ROS1 translocations. Age and performance status (PS) are two pivotal factors to guide treatment decisions regarding the use of chemotherapy in lung cancer patients. Lung cancer is predominantly a disease of the elderly, with more than two-thirds of patients aged ≥65 years, the current definition of 'elderly'...
September 2017: European Journal of Cancer
https://www.readbyqxmd.com/read/28738964/-clinical-research-on-albumin-bound-paclitaxel-based-therapy-in-advanced-lung-cancer
#19
Xu Li, Bin Ai, Ping Zhang, Lin Li, Xiaonan Wu
BACKGROUND: Albumin-bound paclitaxel is a novel paclitaxel formulation formed by the combination of paclitaxel and human serum albumin (HSA) to improve the efficacy of paclitaxel and reduce its adverse reactions. The aim of this retrospective study is to observe the efficacy and safety of albumin-bound paclitaxel-based therapy in the treatment of lung cancer. METHODS: We have enrolled 50 patients with advanced or unresectable retreatment lung cancer who were admitted from November 2011 to December 2014...
July 20, 2017: Zhongguo Fei Ai za Zhi, Chinese Journal of Lung Cancer
https://www.readbyqxmd.com/read/28709816/-current-knowledge-on-perioperative-treatments-of-non-small-cell-lung-carcinomas
#20
REVIEW
S Brosseau, C Naltet, M Nguenang, V Gounant, P Mordant, B Milleron, Y Castier, G Zalcman
Surgery is still the main treatment in early-stage of non-small cell lung cancer with 5-year survival of stage IA patients exceeding 80%, but 5-year survival of stage II patients rapidly decreasing with tumor size, N status, and visceral pleura invasion. The major metastatic risk in such patients has supported clinical research assessing systemic or loco-regional perioperative treatments. Modern phase 3 trials clearly validated adjuvant or neo-adjuvant platinum-based chemotherapy in resected stage I-III patients as a standard treatment of which value has been reassessed several independent meta-analyses, showing a 5% benefit in 5y-survival, and a decrease of the relative risk for death around from 12 to 25%...
June 2017: Revue des Maladies Respiratoires
keyword
keyword
109146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"